Ulster University Logo

Ulster Institutional Repository

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

Biomedical Sciences Research Institute Computer Science Research Institute Environmental Sciences Research Institute Nanotechnology & Advanced Materials Research Institute

McClean, Paula, Gault, Victor A, Harriott, Patrick and Holscher, Christian (2010) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. EUROPEAN JOURNAL OF PHARMACOLOGY, 630 (1-3). pp. 158-162. [Journal article]

Full text not available from this repository.

DOI: 10.1016/j.ejphar.2009.12.023

Abstract

Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process One potential strategy to help prevent this is the normalisation of insulin signalling in the brain Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1) The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus At a dose of 15 nmol in 5 mu l i c v. Liraglutide (P < 0005), Asp(7)GLP-1 (P < 0001), N-glyc-GLP-1 (P < 001), and Pro(9)GLP-1 (P < 0.001). In contrast, the GLP-1 receptor antagonist exendin(9-39)amide impaired LTP (P < 0.001) Co-injection of exendin(9-39) and Liraglutide showed no effect oil LTP. These results clearly demonstrate that Liraglutide and other GLP-1 analogues elicit effects on neurotransmission in the brain Furthermore, GLP-1 peptides are not only effective in modulating insulin-release and achieving glycaemic control in type 2 diabetes, but are also effective in modulating synaptic plasticity These findings are consistent with our previous observations that the novel analogue (Val(8))GLP-1 enhances LTP and reverses the impairments of LTP induced by beta-amyoid fragments Therefore, the drug effects seen here could potentially ameliorate the impairments in neuronal communication and cognitive processes observed in Alzheimer's disease (C) 2009 Elsevier B V. All rights reserved

Item Type:Journal article
Faculties and Schools:Faculty of Life and Health Sciences
Faculty of Life and Health Sciences > School of Biomedical Sciences
Research Institutes and Groups:Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Diabetes
Biomedical Sciences Research Institute > Molecular Medicine
Biomedical Sciences Research Institute > Stratified Medicine
Biomedical Sciences Research Institute > Molecular Medicine > Neuroscience & Neurodegenerative Diseases
ID Code:16500
Deposited By:Dr Paula McClean
Deposited On:24 Nov 2010 16:49
Last Modified:15 Oct 2013 16:33

Repository Staff Only: item control page